SCHEMBL171923

SCHEMBL171923

O=C1NCCCN1[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CDA P32320 13/20 0.67
PDE4D Q08499 1/20 0.43
PDE3A Q14432 1/20 0.43
SLC29A1 Q99808 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20788791 1.00 CDA (0.67) CDAPDE4DPDE3ASLC29A1
SCHEMBL23227176 1.00 CDA (0.67) CDAPDE4DPDE3ASLC29A1
SCHEMBL13895215 1.00 CDA (0.67) CDAPDE4DPDE3ASLC29A1
SCHEMBL23467212 1.00 CDA (0.67) CDAPDE4DPDE3ASLC29A1
SCHEMBL19656107 0.81 CDA (1.00) CDAPDE4DPDE3ASLC29A1
SCHEMBL20788714 0.81 CDA (1.00) CDAPDE4DPDE3ASLC29A1
SCHEMBL12338468 0.81 CDA (1.00) CDAPDE4DPDE3ASLC29A1
SCHEMBL25713917 0.81 CDA (1.00) CDAPDE4DPDE3ASLC29A1
Cedazuridine SCHEMBL25286013 0.80 CDA (1.00) CDAPDE4DPDE3ASLC29A1
Cedazuridine SCHEMBL23227281 0.80 CDA (1.00) CDAPDE4DPDE3ASLC29A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023069529-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS AKIRABIO, INC. (US) 2023-04-27 WO claimed
US-20230122664-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS CUSTOMERS BANK 2023-04-20 US claimed
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC 2023-02-23 US claimed
WO-2021211890-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC (US) 2021-10-21 WO claimed
US-11938143-B2 Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers AKIRABIO, INC. (US) 2024-03-26 US disclosed
US-20230303609-A1 2′-DEOXY-2′,2′-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME TAIHO PHARMACEUTICAL CO., LTD. (JP) 2023-09-28 US disclosed
US-20230271996-A1 PROCESS FOR PREPARING CEDAZURIDINE SCINOPHARM TAIWAN, LTD. (TW) 2023-08-31 US disclosed
WO-2023069529-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS AKIRABIO, INC. (US) 2023-04-27 WO disclosed
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA AKIRABIO INC (US) 2023-04-20 US disclosed
US-20230122664-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS CUSTOMERS BANK 2023-04-20 US disclosed
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS ADIMABIO LLC 2023-02-23 US disclosed
US-20220411457-A1 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-12-29 US disclosed
US-20150210730-A1 CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-07-30 US disclosed
US-8951987-B2 Certain compounds, compositions and methods OTSUKA PHARMACEUTICALS CO., LTD. (JP) 2015-02-10 US disclosed
US-20140186335-A1 Certain Compounds, Compositions and Methods EISAI INC. (US) 2014-07-03 US disclosed
US-8268800-B2 Certain compounds, compositions and methods EISAI INC. (US) 2012-09-18 US disclosed
US-8268800-B2 Certain compounds, compositions and methods EISAI INC. (US) 2012-09-18 US disclosed
EP-2207786-B1 2'-FLUORO-2'-DEOXYTETRAHYDROURIDINES AS CYTIDINE DEAMINASE INHIBITORS EISAI INC (US) 2012-03-07 EP disclosed
US-20090137521-A1 Certain Compounds, Compositions and Methods TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-05-28 US disclosed
US-20090137521-A1 Certain Compounds, Compositions and Methods TAIHO PHARMACEUTICAL CO., LTD. (JP) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230122664-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB CDA 4/4885PDE4D 637/4885PDE3A 572/4885
US-11938143-B2 Compositions comprising 2′-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers TYMP, HBZ, CDA CDA 3/4885PDE4D 603/4885PDE3A 585/4885
US-20140186335-A1 Certain Compounds, Compositions and Methods DUT, TYMP, DPYD CDA 134/4885PDE4D 907/4885PDE3A 944/4885
US-20220411457-A1 2'-DEOXY-2',2'-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME DCTD, DUT, DHODH CDA 75/4885PDE4D 230/4885PDE3A 1942/4885
US-20150210730-A1 CERTAIN COMPOUNDS, COMPOSITIONS AND METHODS DUT, TYMP, DPYD CDA 134/4885PDE4D 907/4885PDE3A 944/4885
US-20230271996-A1 PROCESS FOR PREPARING CEDAZURIDINE DUT, CCNB1, EZH1 CDA 87/4885PDE4D 2766/4885PDE3A 2941/4885
US-20090137521-A1 Certain Compounds, Compositions and Methods DUT, TYMP, DPYD CDA 134/4885PDE4D 907/4885PDE3A 944/4885
US-20230303609-A1 2′-DEOXY-2′,2′-DIFLUOROTETRAHYDROURIDINES WITH HIGH PURITY AND METHODS OF MAKING THE SAME DCTD, DUT, DHODH CDA 67/4885PDE4D 226/4885PDE3A 1987/4885
US-20230055298-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE, THALASSEMIA, AND CANCERS TYMP, HBZ, HBB CDA 4/4885PDE4D 637/4885PDE3A 572/4885
US-20230123277-A1 COMPOSITIONS COMPRISING 2'-DEOXYCYTIDINE ANALOGS AND USE THEREOF FOR THE TREATMENT OF SICKLE CELL DISEASE AND THALASSEMIA HBB, HBZ, TYMP CDA 6/4885PDE4D 424/4885PDE3A 418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.